These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 30733317)

  • 41. [
    Van Weehaeghe D; Koole M; Schmidt ME; Deman S; Jacobs AH; Souche E; Serdons K; Sunaert S; Bormans G; Vandenberghe W; Van Laere K
    Eur J Nucl Med Mol Imaging; 2019 Sep; 46(10):2051-2064. PubMed ID: 31243495
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Novel
    Li S; Cai Z; Zheng MQ; Holden D; Naganawa M; Lin SF; Ropchan J; Labaree D; Kapinos M; Lara-Jaime T; Navarro A; Huang Y
    J Nucl Med; 2018 Jan; 59(1):140-146. PubMed ID: 28747521
    [TBL] [Abstract][Full Text] [Related]  

  • 43. PET imaging of P2X
    Beaino W; Janssen B; Kooijman E; Vos R; Schuit RC; O'Brien-Brown J; Kassiou M; van Het Hof B; Vugts DJ; de Vries HE; Windhorst AD
    J Neuroinflammation; 2020 Oct; 17(1):300. PubMed ID: 33054803
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Synthesis and evaluation of candidate PET radioligands for corticotropin-releasing factor type-1 receptors.
    Lodge NJ; Li YW; Chin FT; Dischino DD; Zoghbi SS; Deskus JA; Mattson RJ; Imaizumi M; Pieschl R; Molski TF; Fujita M; Dulac H; Zaczek R; Bronson JJ; Macor JE; Innis RB; Pike VW
    Nucl Med Biol; 2014 Jul; 41(6):524-35. PubMed ID: 24793011
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Preclinical characterization of [
    Koike T; Constantinescu CC; Ikeda S; Nishi T; Sunahara E; Miyamoto M; Cole P; Barret O; Alagille D; Papin C; Morley T; Fowles K; Seibyl J; Tamagnan G; Kuroita T
    Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1148-1156. PubMed ID: 34651220
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Translation of HDAC6 PET Imaging Using [
    Celen S; Rokka J; Gilbert TM; Koole M; Vermeulen I; Serdons K; Schroeder FA; Wagner FF; Bleeser T; Hightower BG; Hu J; Rahal D; Beyzavi H; Vanduffel W; Van Laere K; Kranz JE; Hooker JM; Bormans G; Cawthorne CJ
    ACS Chem Neurosci; 2020 Apr; 11(7):1093-1101. PubMed ID: 32159328
    [TBL] [Abstract][Full Text] [Related]  

  • 47. JNJ-40255293, a novel adenosine A2A/A1 antagonist with efficacy in preclinical models of Parkinson's disease.
    Atack JR; Shook BC; Rassnick S; Jackson PF; Rhodes K; Drinkenburg WH; Ahnaou A; Te Riele P; Langlois X; Hrupka B; De Haes P; Hendrickx H; Aerts N; Hens K; Wellens A; Vermeire J; Megens AA
    ACS Chem Neurosci; 2014 Oct; 5(10):1005-19. PubMed ID: 25203719
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Blockade of the brain histamine H3 receptor by JNJ-39220675: preclinical PET studies with [¹¹C]GSK189254 in anesthetized baboon.
    Logan J; Carruthers NI; Letavic MA; Sands S; Jiang X; Shea C; Muench L; Xu Y; Carter P; King P; Fowler JS
    Psychopharmacology (Berl); 2012 Oct; 223(4):447-55. PubMed ID: 22614669
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Ex vivo delta opioid receptor autoradiography: CNS receptor occupancy of two novel compounds over their antihyperalgesic dose range.
    Codd EE; Ma J; Zhang SP; Stone DJ; Colburn RW; Brandt MR; Chevalier KM; Zhu Y; Peng S; Cai C; Acton PD; Flores CM
    Pharmacol Biochem Behav; 2010 Aug; 96(2):130-5. PubMed ID: 20438745
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Synthesis and in vitro characterization of a P2X7 radioligand [
    Jin H; Han J; Resing D; Liu H; Yue X; Miller RL; Schoch KM; Miller TM; Perlmutter JS; Egan TM; Tu Z
    Eur J Pharmacol; 2018 Feb; 820():8-17. PubMed ID: 29225193
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Characterization in nonhuman primates of (R)-[
    Zheng M; Ahmed H; Smart K; Xu Y; Holden D; Kapinos M; Felchner Z; Haider A; Tamagnan G; Carson RE; Huang Y; Ametamey SM
    Eur J Nucl Med Mol Imaging; 2022 Jun; 49(7):2153-2162. PubMed ID: 35107627
    [TBL] [Abstract][Full Text] [Related]  

  • 52. PET imaging of α4β2* nicotinic acetylcholine receptors: quantitative analysis of 18F-nifene kinetics in the nonhuman primate.
    Hillmer AT; Wooten DW; Slesarev MS; Ahlers EO; Barnhart TE; Murali D; Schneider ML; Mukherjee J; Christian BT
    J Nucl Med; 2012 Sep; 53(9):1471-80. PubMed ID: 22851633
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Radiosynthesis and preclinical evaluation of 18F-F13714 as a fluorinated 5-HT1A receptor agonist radioligand for PET neuroimaging.
    Lemoine L; Becker G; Vacher B; Billard T; Lancelot S; Newman-Tancredi A; Zimmer L
    J Nucl Med; 2012 Jun; 53(6):969-76. PubMed ID: 22577236
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Substituted 5,6-(Dihydropyrido[3,4-d]pyrimidin-7(8H)-yl)-methanones as P2X7 Antagonists.
    Ziff J; Rudolph DA; Stenne B; Koudriakova T; Lord B; Bonaventure P; Lovenberg TW; Carruthers NI; Bhattacharya A; Letavic MA; Shireman BT
    ACS Chem Neurosci; 2016 Apr; 7(4):498-504. PubMed ID: 26754558
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Synthesis and evaluation of 11C-LY2795050 as a κ-opioid receptor antagonist radiotracer for PET imaging.
    Zheng MQ; Nabulsi N; Kim SJ; Tomasi G; Lin SF; Mitch C; Quimby S; Barth V; Rash K; Masters J; Navarro A; Seest E; Morris ED; Carson RE; Huang Y
    J Nucl Med; 2013 Mar; 54(3):455-63. PubMed ID: 23353688
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [3H]A-804598 ([3H]2-cyano-1-[(1S)-1-phenylethyl]-3-quinolin-5-ylguanidine) is a novel, potent, and selective antagonist radioligand for P2X7 receptors.
    Donnelly-Roberts DL; Namovic MT; Surber B; Vaidyanathan SX; Perez-Medrano A; Wang Y; Carroll WA; Jarvis MF
    Neuropharmacology; 2009 Jan; 56(1):223-9. PubMed ID: 18602931
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Transient P2X7 Receptor Antagonism Produces Lasting Reductions in Spontaneous Seizures and Gliosis in Experimental Temporal Lobe Epilepsy.
    Jimenez-Pacheco A; Diaz-Hernandez M; Arribas-Blázquez M; Sanz-Rodriguez A; Olivos-Oré LA; Artalejo AR; Alves M; Letavic M; Miras-Portugal MT; Conroy RM; Delanty N; Farrell MA; O'Brien DF; Bhattacharya A; Engel T; Henshall DC
    J Neurosci; 2016 Jun; 36(22):5920-32. PubMed ID: 27251615
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Preclinical Evaluation of
    Declercq L; Rombouts F; Koole M; Fierens K; Mariën J; Langlois X; Andrés JI; Schmidt M; Macdonald G; Moechars D; Vanduffel W; Tousseyn T; Vandenberghe R; Van Laere K; Verbruggen A; Bormans G
    J Nucl Med; 2017 Jun; 58(6):975-981. PubMed ID: 28232614
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Preclinical evaluation of [18F]2FNQ1P as the first fluorinated serotonin 5-HT6 radioligand for PET imaging.
    Becker G; Colomb J; Sgambato-Faure V; Tremblay L; Billard T; Zimmer L
    Eur J Nucl Med Mol Imaging; 2015 Mar; 42(3):495-502. PubMed ID: 25331460
    [TBL] [Abstract][Full Text] [Related]  

  • 60. (11)C-MK-8278 PET as a tool for pharmacodynamic brain occupancy of histamine 3 receptor inverse agonists.
    Van Laere KJ; Sanabria-Bohórquez SM; Mozley DP; Burns DH; Hamill TG; Van Hecken A; De Lepeleire I; Koole M; Bormans G; de Hoon J; Depré M; Cerchio K; Plalcza J; Han L; Renger J; Hargreaves RJ; Iannone R
    J Nucl Med; 2014 Jan; 55(1):65-72. PubMed ID: 24263088
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.